arrow
E

Eva Gonçalvesová

university of milano-bicocca
H指数:25
被引数:1.1万
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis

心血管-肾脏-代谢综合征中的性别差异:FINE-HEART合并分析

2026-03-010
PRE
Who Recovers? Clinical and Echocardiographic Predictors of Reverse Remodeling in HFrEF

谁会恢复?HFrEF患者逆转重构的临床和超声心动图预测因子

2026-01-010
OAAI
Contemporary implementation of guideline-directed medical and device therapies in heart failure: Insights from the Central/Eastern Europe Quality of Care Centres Survey

当代心衰指南推荐药物与器械疗法的实施:来自中/东欧护理质量中心调查的见解

2025-09-240
PRE
Necrosis-like cell death modes in heart failure: the influence of aetiology and the effects of RIP3 inhibition

心力衰竭中的类坏死性细胞死亡模式:病因学的影响及RIP3抑制的作用

2025-03-150
OA
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
2025-01-011
OA
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
2024-10-2443
PRE
EMPAGLIFLOZIN AND ITS CARDIOPROTECTIVE EFFECTS IN THE HEART DURING VOLUME OVERLOAD IN AN EXPERIMENTAL MODEL INDUCED BY AORTOCAVAL FISTULA
2024-09-010
PRE
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial

射血分数轻度降低或保留的心力衰竭患者的基线特征: finearts-hf试验

2024-05-1110
OAAI
LOWER MIR-126 PLASMA CONCENTRATIONS IN HUMAN PULMONARY ARTERIAL HYPERTENSION
2024-05-010
OA
Analysis of the serum levels of RIP3 and Drp1 in patients with heart failure
2024-03-212
OAAI
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
2022-05-2225
OAAI
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial
2022-01-0176
OA
Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction
2021-12-1326
OA
Amended STRONG-HF study design
2021-10-0412
OA
HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge

关于非LVAD专业医疗保健提供者的LVAD支持患者管理的ESC立场文件的HFA第3部分: 住院和出院

2021-09-2812
OA
HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community
2021-09-1410
OA
Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department
2021-09-1410
OA
Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary
2021-08-2227
OAAI
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
2021-01-14413
OAAI
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
2020-10-2761
OAAI